Bayer shares up after first trial win over Roundup
- Wall St ends up with Goldman; Dow posts biggest weekly rise since June
- Goldman Sachs (GS) Smashes Analyst 3Q Views on Robust M&A and Underwriting Activity
- Tesla (TSLA) Stock: Jefferies Raises Price Target on Higher Capacity Ramp and Sustained Demand, Berlin Giga Will Set New Design and Assembly Standards Says Analyst
- Food, fuels lift U.S. import prices in September
- SEC to Allow First Ever Bitcoin (BTC) ETF - Report
FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen, Germany February 27, 2019. REUTERS/Wolfgang Rattay
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
BERLIN (Reuters) - Shares in Bayer AG rose 2.5% in pre-market trade on Wednesday after the German agricultural and pharmaceuticals firm won its first trial over claims its Roundup weedkiller causes cancer.
A California jury found that the herbicide was not a substantial cause of a child's rare form of non-Hodgkin's lymphoma, the company said on Tuesday. The verdict is the fourth involving Roundup and the first in the company's favor.
Roundup-related lawsuits have dogged Bayer since it acquired the brand as part of its $63 billion purchase of agricultural seeds and pesticides maker Monsanto in 2018.
(Reporting by Emma Thomasson; Editing by Muralikumar Anantharaman)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Earthquake of magnitude 4.8 strikes Bali, kills three
- Seven Hong Kong activists jailed over unauthorised protest in 2020
- Pressure to devalue Brazil real to ease in 2022, cenbank official says
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!